ClinicalTrials.gg
CompletedNCT01448070Updated Feb 27, 2017

Comparison of Human Insulin Produced by the Current Process and the NN729 Process in Healthy Volunteers

A Phase 1 interventional study of human insulin in Diabetes and Healthy, sponsored by Novo Nordisk A/S. Completed at 1 site in United Kingdom. Open to male participants aged 18 Years to 50 Years, including healthy volunteers. Per ClinicalTrials.gov, last updated 2017-02-27.

Sponsored by Novo Nordisk A/S · Phase 1, Interventional, and Treatment

From the registry’s dates

  • Registered 8 years 11 months after the study started (first participant enrolled Oct 2002, registered Oct 2011).

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Phase 1
Study type
Interventional
Enrollment
28
Allocation
Randomized
Ages
18 Years to 50 Years
Sex
Male
01

Where this study stands

Counted across the records on this site · 2026-11-17

Among 41 studies testing Insulin, Regular, Human in Diabetes Mellitus — 2 open to participants now, 2 under way, none of them phase 3. Insulin, Regular, Human · Diabetes Mellitus.

Enrollment
26th of 41
28 · median 60
Started
2002
with 4 others
Phase 1
8 of 41
1 open now
Registered
28th of 41
by date
Lead sponsor
19 of 41
Novo Nordisk A/S

Among the 41 studies testing Insulin, Regular, Human in Diabetes Mellitus, this one is the 26th largest by enrollment, is one of 5 that started in 2002, is one of 8 in phase 1, and was the 28th registered.

Diabetes Mellitus

8,293 studies on the registry are indexed under Diabetes Mellitus; 1,072 are open to participants now.

Browse Diabetes Mellitus studies →

Open to participants now

2 of the 41 studies testing Insulin, Regular, Human in Diabetes Mellitus are open now, in 1 country. Recruiting first, the newest first:

By country, each count listing its studies:

All 2 open studies →

About Insulin, Regular, Human

Insulin, Regular, Human: first FDA approval 1982 (HUMULIN R PEN), first EMA approval 1997. What it is approved for, and how studies give it, is on its page →

Who these studies take

Of the 648 Diabetes Mellitus studies recruiting now, 357 (55%) set no upper age limit and 195 (30%) stop at 75 or younger; 88 take children under 18; 182 take healthy volunteers.

This study: 18 Years to 50 Years · male · healthy volunteers too.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Get alerts for this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 41 studies testing Insulin, Regular, Human in Diabetes Mellitus, or all of them as a file.
02

Study summary

This trial is conducted in Europe. The aim of this trial is to show that the product of the new production process has a similar pharmacological profile to the traditional process used for the current commercial product Actrapid®.

03

Conditions studied

  • Diabetes
  • Healthy

Browse trials for

04

Who can participate

Ages eligible
18 Years to 50 Years
Sexes eligible
Male
Accepts healthy volunteers
Yes

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  • Normal findings in medical history and physical examination unless the investigator considers any abnormality to be clinically irrelevant
  • Fasting blood glucose below or equal to 6 mmol/L
  • (BMI) 22.0-27.0 kg/m\^2 (both inclusive)

Exclusion criteria

Exclusion Criteria:

  • Participated in another clinical study with an drug within the last 4 weeks
  • Any condition requiring the regular use of any medication, including herbal remedies, over the counter medicines and vitamins. Occasional paracetamol is acceptable
  • Known or suspected allergy to the trial product or related products
  • Family history of type 1 diabetes
Terms in these criteria, in plain language(2)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

BMI (body mass index)

Weight in kilograms divided by height in metres squared. Example: 70 kg and 1.75 m gives 70 ÷ (1.75 × 1.75) ≈ 22.9.

What counts as overweight or obesity differs between countries (some use lower cut-offs), so go by the range the study states.

Investigational drug or device

A drug or device being studied in a clinical trial.

It may be new, or already approved and being studied for another use, dose or form. Criteria often leave out people who took part in another study of one within a recent period, commonly 30 days or five half-lives.

05

Study design

Phase
Phase 1
Primary purpose
Treatment
Allocation
Randomized
Intervention model
Crossover assignment
Masking
Double (Participant, Investigator)
Enrollment
28 participants (actual)

Study arms

  • Experimental
    NN729 manufacturing process

    Drug: human insulin

  • Active comparator
    Current manufacturing process

    Drug: human insulin

Interventions

  • Single dose of 0.2 IU/kg, administered subcutaneously (under the skin)

06

What researchers measure

Primary outcomes

  1. AUC (area under the curve) 0-8h (human insulin)

  2. Cmax (maximum plasma concentration)

  3. Area under the curve (glucose infusion rate (GIR)), 0-8h

Secondary outcomes

  1. tmax (time to reach maximum)

  2. t½ (terminal half-life)

  3. GIR (glucose infusion rate) max

  4. tGIR (glucose infusion rate) max

  5. Area under the curve (C-peptide, 0-8h)

  6. Physical examinations and vital signs

07

Study locations

1 site
  • Novo Nordisk Investigational Site
    Manchester, M15 6SH, United Kingdom
08

References and documents

09

Timeline

Tracking since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reachedSimilar studies: half by the dot; the band is the middle halfHalf of similar studies reached it by the dot; the band is the middle half, from a quarter to three quarters

Ran from Oct 2002 to primary completion in Dec 2002, 2 months.

Of 171 industry-sponsored phase 1 interventional studies under Diabetes Mellitus, half reached primary completion within 6 months of starting (the median), counting those still running; a quarter within 2 and three quarters within 10. This study's 2 months is below that.

Counting every sponsor, half of 247 studies reached it within 7 months; a quarter within 3 and three quarters within 17.

How these figures are worked out, and which studies are left out of them.

Registered
Oct 5, 2011
First posted
Oct 7, 2011
StartActual
Oct 15, 2002
Primary completionActual
Dec 20, 2002
CompletionActual
Dec 20, 2002
Last update
Feb 27, 2017
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Feb 27, 2017, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
10

Registry details

Key details

Study ID
NCT01448070
Lead sponsor
Novo Nordisk A/S
Responsible party
Sponsor
First posted
Oct 7, 2011
Start date
Oct 15, 2002
Primary completion
Dec 20, 2002
Completion
Dec 20, 2002
Last update
Feb 27, 2017

Study contacts

Global Clinical Registry (GCR, 1452)
study director · Novo Nordisk A/S

Oversight

Data monitoring committee
No
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is completed, as verified in Feb 2017. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Studies of the drug tested here: Insulin, Regular, Human

Start the discussion